Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer
- Authors
- Oh, SC; Park, KH; Choi, IK; Yoon, SY; Kim, SJ; Seo, JH; Choi, CW; Kim, BS; Shin, SW; Kim, JS; Kim, YH
- Issue Date
- 14-Mar-2005
- Publisher
- NATURE PUBLISHING GROUP
- Keywords
- docetaxel; cisplatin; UFT; stomach neoplasms
- Citation
- BRITISH JOURNAL OF CANCER, v.92, no.5, pp 827 - 831
- Pages
- 5
- Indexed
- SCIE
SCOPUS
- Journal Title
- BRITISH JOURNAL OF CANCER
- Volume
- 92
- Number
- 5
- Start Page
- 827
- End Page
- 831
- URI
- https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/19784
- DOI
- 10.1038/sj.bjc.6602446
- ISSN
- 0007-0920
1532-1827
- Abstract
- We conducted this study to ascertain the efficacy and toxicity of docetaxel and cisplatin combined with oral UFT and leucovorin as a first-line treatment for patients with advanced gastric cancer. In all, 52 patients received courses of docetaxel 60 mg m(-2) intravenously (i.v.) for 1 h and then cisplatin 75 mg m(-2) i.v. for 2 h on day 1. Oral UFT at 400-600 mg day(-1), as determined by body surface area, and leucovorin at 75 mg day(-1) were administered for 21 consecutive days from day 1, and this was followed by a 7-day drug-free interval. A total of 225 courses were administered, and the median number of courses per patient was four. Four complete responses (7.7%) and 22 partial responses (42.3%) were achieved, giving an overall response rate of 50% (95% Confidence Interval: 36.4-63.6%). The major toxicity was neutropenia, which reached grade 3/4 in 36 patients (69.3%). Grade 3/4 nausea and vomiting was observed in 12 patients (23.1%). Median time to progression was 22 weeks (4 to 156+ weeks), median survival duration was 48 weeks (4 to 156+ weeks), and median response duration was 24 weeks (6-152 weeks). We conclude that docetaxel, cisplatin, oral UFT, and leucovorin combination chemotherapy is effective and tolerable for the treatment of advanced gastric cancer.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - 2. Clinical Science > Department of Medical Oncology and Hematology > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.